SNPS.NASDAQSynopsys INC

Form 4: Synopsys Executive Chair Aart de Geus Executes Stock Options and Sells Shares

Sentiment:

SEC Form 4 Filing


Aart de Geus, Executive Chair of Synopsys, exercised stock options and sold shares in multiple transactions on June 28, 2024, and July 1, 2024, according to a Form 4 filing with the SEC.

Summary

  • Aart de Geus, the Executive Chair of Synopsys Inc., engaged in transactions involving Synopsys common stock.
  • On June 28, 2024, and July 1, 2024, de Geus exercised non-qualified stock options to acquire 11,185 and 5,893 shares, respectively, at a price of $89.76 per share.
  • Concurrently, de Geus sold 11,185 shares on June 28, 2024, at a weighted average price of $603.9389, and 5,893 shares on July 1, 2024, at a weighted average price of $601.9962.
  • Following these transactions, de Geus directly owns 106,983 shares of Synopsys common stock.
  • De Geus also indirectly owns 122,240 shares through a family trust, 14,500 shares through a partnership, and 186,551 shares through a separate property trust.
  • The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 25, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading strategy (Rule 10b5-1) and do not necessarily reflect a change in the executive's outlook on the company.

Industry Context

Insider transactions are routinely monitored and reported to the SEC, providing transparency into the actions of company executives and their confidence in the company's prospects; the use of a pre-arranged trading plan (Rule 10b5-1) is a common practice to avoid accusations of trading on inside information.

Comparison to Industry Standards

  • Executive stock option exercises and sales are common in the tech industry, particularly among companies like Synopsys, Cadence Design Systems, and Mentor Graphics (now Siemens EDA).
  • These transactions are often part of executives' compensation packages and long-term financial planning.
  • The reported weighted average sale prices are consistent with Synopsys's recent stock performance, indicating market valuation alignment.

Stakeholder Impact

  • The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
  • However, the pre-planned nature of the transactions mitigates concerns about insider information influencing the sales.

Key Dates

DateDescription
12/12/2019Date Non-Qualified Stock Options were granted
03/25/2024Date of adoption of Rule 10b5-1 trading plan
06/28/2024Date of stock option exercise and share sale
07/01/2024Date of stock option exercise and share sale
07/02/2024Date of Form 4 filing
12/12/2025Expiration date of Non-Qualified Stock Options

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.